(NASDAQ:OPXA) shares saw light trading volume with 0 shares changing hands by the end of trading on Tuesday. Overall, volume was down 100.00% under the stocks normal daily volume.
Short traders are more bullish lately if you take a look at the downtick in short interest. The stock recorded a fall in short interest from August 31, 2017 to September 15, 2017 of -0.09%. Short shares fell from 536,176 to 535,691 over that timeframe. Days to cover increased 2.0 to 4.0 and the short interest percentage is 0.07% as of September 15.
Here are a few substantial investment firms who have updated their positions. Vanguard Group Inc trimmed its ownership by shedding 93,181 shares a decrease of 95.8% in the quarter. Vanguard Group Inc now controls 4,062 shares worth $3,000. The total value of its holdings decreased 95.9%. Morgan Stanley cut its position by selling 1,359 shares a decrease of 91.3% from 03/31/2017 to 06/30/2017. Morgan Stanley owns 130 shares valued at $0. The value of the position overall is down by 100.0%.
Blackrock Inc. augmented its stake by buying 508 shares an increase of 16.9%. Blackrock Inc. currently owns 3,518 shares with a value of $2,000. The total value of its holdings decreased 0.0%. Kcg Holdings, Inc. reduced its holdings by selling 42,678 shares a decrease of 70.8% as of 06/30/2017. Kcg Holdings, Inc. now holds 17,578 shares worth $11,000. The value of the position overall is down by 77.1%.
The company is down by 9.36% percent from yesterday’s close. Shares are trading at $0.97 just a bit higher than $0.89, the 50 day moving average and significantly above the 200 day moving average of $0.77. The 50 day moving average was up $0.08 whereas the 200 day average was up by +25.8426%.
As of the last earnings report the EPS was $-0.72 and is estimated to be $-0.47 for the current year with 7,657,000 shares presently outstanding. Next quarter’s EPS is expected be $-0.12 with next year’s EPS anticipated to be $-0.22.
Opexa Therapeutics, Inc. (Opexa), launched on March 15, 1991, is a biopharmaceutical company. The Company is involved in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Business’s T-cell technology. The Business’s product candidates include Tcelna and OPX-212..